CM313, a Novel Anti-CD38 Antibody, As a Potential Treatment for Primary Immune Thrombocytopenia: A Phase II Trial

医学 内科学 美罗华 临床终点 血小板 胃肠病学 免疫学 抗体 临床试验
作者
Yunfei Chen,Yanmei Xu,Xuan Cao,Feng Xue,Ting Sun,Wei Liu,Mankai Ju,Rongfeng Fu,Xiao Fan Liu,Xinyue Dai,Huiyuan Li,Renchi Yang,Lei Zhang
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 1206-1206 被引量:2
标识
DOI:10.1182/blood-2023-188664
摘要

Background: Primary immune thrombocytopenia (ITP) is an autoimmune disease characterized by autoantibody-mediated platelet destruction. Antiplatelet-specific plasma cells (PCs) have been identified in ITP patients, making PCs depletion a potential treatment for ITP. CM313, a novel anti-CD38 monoclonal antibody currently under investigation in a phase I trial for multiple myeloma, has demonstrated targeted depletion of CD38-positive cells, including PCs. This phase II trial (NCT05694767) was designed to assess the safety and efficacy of CM313 in ITP patients. Methods: The open-label phase II trial consisted of a 4-week screening period, an 8-week treatment period, and a 16-week follow-up period. The main inclusion criteria were patients (age ≥18 years) with ITP and a platelet count <30×10 9/L, who did not response to or relapsed after glucocorticoid therapy and at least one second-line therapy (including rituximab and/or thrombopoietin receptor agonists [TPO-RAs]). Eligible patients received CM313 intravenously at a dose of 16 mg/kg weekly for a total of 8 weeks. The participants were requested to maintain the stable doses of glucocorticoids or TPO-RAs for 4 weeks prior to receiving the first dose without dose escalation during the study. Prophylactic medication, including glucocorticoids, antihistamines, and acetaminophen, was administered to all patients before and after the infusion. The primary endpoints were the percentage of patients with a platelet count ≥50×10 9/L within 8 weeks after the first dose (platelet count must be consecutive on at least 2 occasions with an interval of at least 1 day) and the incidence/severity of adverse events during the study period. Results: As of June 30, 2023, a total of 21 patients had been enrolled in the study and 7 subjects had completed 8 doses of the treatment with at least 8 weeks of follow-up. The 7 subjects consisted of 2 males and 5 females, with a median age of 40 years (range 18-56), a median weight of 62 kg (range 52-93), a median duration of ITP of 30 months (range 12-200) and a median baseline platelet count of 8×10 9/L (range 2-24). Of the 7 patients, 100.0% (7/7) achieved a platelet count ≥50×10 9/L within 8 weeks after the first dose, with a median time to response of 1 week (range 1-3). Furthermore, 4 out of 7 patients (57.1%) maintained a platelet count of ≥50×10 9/L until week 16, while 2 patients experienced a relapse at week 6 and 1 patient had a relapse at week 13. Platelet count (expressed as the median with the interquartile range) of the 7 patients from baseline to week 23 are shown in Figure 1. Of all 21 patients, 6 (6/21, 28.6%) had an infusion-related reaction (IRR) at the first dose but none at subsequent doses. The severity of IRR was grade 1 or 2 (according to CTCAE version 5.0). Conclusion: CM313, a novel anti-CD38 monoclonal antibody, has demonstrated tolerable safety and preliminary efficacy in refractory/relapsed ITP patients. Figure 1: Platelet count in 7 patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
炙热从蕾发布了新的文献求助10
刚刚
1秒前
1秒前
1秒前
2秒前
oceanwater123完成签到 ,获得积分10
3秒前
赘婿的应助被aaXZS采纳,获得10
3秒前
dpurity完成签到,获得积分20
3秒前
万能图书馆的应助被如飘瑞雪采纳,获得10
3秒前
3秒前
英俊的铭的应助被专注的丹珍采纳,获得10
4秒前
lzx发布了新的文献求助10
4秒前
CHEN发布了新的文献求助10
4秒前
柳七发布了新的文献求助10
5秒前
6秒前
迅速河马完成签到,获得积分20
6秒前
6秒前
6秒前
董梓竣发布了新的文献求助50
6秒前
cc发布了新的文献求助10
7秒前
oceanwater123关注了科研通微信公众号
7秒前
吃橘子吗发布了新的文献求助10
7秒前
8秒前
科目三的应助被贾香运采纳,获得100
8秒前
8秒前
8秒前
8秒前
9秒前
认真芷容完成签到,获得积分0
9秒前
博纳清发布了新的文献求助10
9秒前
思源的应助被南经采纳,获得10
9秒前
cz发布了新的文献求助10
10秒前
可口可乐发布了新的文献求助10
10秒前
10秒前
任性山芙发布了新的文献求助10
11秒前
初景的应助被Quj采纳,获得20
12秒前
13秒前
共享精神的应助被卡桃康采纳,获得10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178582
求助须知:如何正确求助?哪些是违规求助? 9569391
关于积分的说明 21804062
捐赠科研通 7773535
什么是DOI,文献DOI怎么找? 3432871
关于科研通互助平台的介绍 2556860
邀请新用户注册赠送积分活动 2478451